Indeed, several pieces of evidence suggest the use of pan‐PI3K inhibitors in topical administration.26, 27 Further studies are underway and will be performed to demonstrate the efficacy of compound 64 in different mouse models of chronic inflammation, for which topical administration would be beneficial, such as asthma and psoriasis, and to evaluate its systemic toxicity. The gene discussed is PIK3CA; the disease is asthma.